These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39687611)

  • 21. Comparison of proton-based definitive chemoradiotherapy and surgery-based therapy for esophageal squamous cell carcinoma: a multi-center retrospective Japanese cohort study.
    Ogawa K; Ishikawa H; Toyozumi T; Noma K; Kono K; Hojo H; Tamamura H; Azami Y; Ishida T; Nabeya Y; Iwata H; Araya M; Tokumaru S; Maruo K; Oda T; Matsubara H
    Esophagus; 2024 Oct; 21(4):484-494. PubMed ID: 38844703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tislelizumab combined with nab-paclitaxel and cisplatin as the more effective chemoimmunotherapy strategy in the neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma: A prospective, two-cohort, phase 2 trial.
    Wang J; Li B; Zhang Y; Luo X; Zhang Y; Li H; Pan Y; Shao L; Zheng S; Yuan C; Li Y; Zheng Q; Sun S; Zhao W; Sun Y
    Int J Cancer; 2024 Dec; ():. PubMed ID: 39686540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
    Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
    Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant immunotherapy plus chemotherapy in high altitude natives with resectable esophageal squamous cell carcinoma in Tibet.
    Sui X; Danzeng D; Ni P; Geng J; Gesang P; Zhaxi R; Wei Y
    Asian J Surg; 2024 Dec; ():. PubMed ID: 39645490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non-Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study.
    Gao Z; Teng J; Qiao R; Qian J; Pan F; Ma M; Lu J; Zhang B; Chu T; Zhong H
    JMIR Res Protoc; 2024 Nov; 13():e64950. PubMed ID: 39514267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.
    Randon G; Lonardi S; Fassan M; Palermo F; Tamberi S; Giommoni E; Ceccon C; Di Donato S; Fornaro L; Brunetti O; De Vita F; Bittoni A; Chini C; Spallanzani A; Nappo F; Bethaz V; Strippoli A; Latiano T; Cardellino GG; Giuliani F; Morano F; Niger M; Raimondi A; Prisciandaro M; Pircher CC; Sciortino C; Marchesi S; Garattini SK; Airò G; Miceli R; Di Bartolomeo M; Pietrantonio F
    Lancet Oncol; 2024 Dec; 25(12):1539-1550. PubMed ID: 39557058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant therapy of sequential TACE, camrelizumab, and apatinib for single huge hepatocellular carcinoma (NEO-START): study protocol for a randomized controlled trial.
    Hao Y; Xie F; Zhou Y; Li C; Zhang X; Shen J; Yao M; Sun X; Zhou J; Wen T; Peng W
    Trials; 2024 Jul; 25(1):490. PubMed ID: 39030637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detrimental Impact of Chemotherapy Dose Reduction or Discontinuation in Early Stage Triple-Negative Breast Cancer Treated With Pembrolizumab and Neoadjuvant Chemotherapy: A Multicenter Experience.
    Krishnan J; Patel A; Roy AM; Alharbi M; Kapoor A; Yao S; Khoury T; Hong CC; Held N; Chakraborty A; Kaliniski P; Salman A; Catalfamo K; Attwood K; Kirtani V; Shaikh SS; Chaudhary LN; Gandhi S
    Clin Breast Cancer; 2024 Dec; 24(8):e701-e711.e2. PubMed ID: 39198116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pembrolizumab plus cetuximab with neoadjuvant chemotherapy for head and neck squamous cell carcinoma.
    Yao Z; Wang J; Jiang Y; Zhang Y; Liu J; Dai L; Shen S; Zhou X; Liu Q; Zheng L; Qian M; Li J
    Head Neck; 2025 Jan; 47(1):289-299. PubMed ID: 39138647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y; Chen W; Dong L; Duan L; Gao P
    Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of efficacy and safety of neoadjuvant immunochemotherapy in young and elderly patients with IIA-IIIB non-small-cell lung cancer in real-world practice.
    Liu J; Huang X; Yang Y; Lv W; Wang Y; Xia P; Hu J
    BMC Pulm Med; 2024 Nov; 24(1):592. PubMed ID: 39614293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patients with complete clinical response after neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: A Markov decision analysis of esophagectomy versus active surveillance.
    Bondzi-Simpson A; Ribeiro T; Grant A; Ko M; Coburn N; Hallet J; Kulkarni GS; Kidane B
    J Thorac Cardiovasc Surg; 2024 Dec; 168(6):1538-1549.e1. PubMed ID: 38649112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CT-based delta-radiomics for predicting pathological response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma: a multicenter study.
    Zheng Y; Mei P; Wang M; Luo Q; Li H; Ding C; Zhang K; Chen L; Gu J; Li Y; Guo T; Zhang C; Yao W; Wei L; Liao Y; Han X; Shi H
    BMC Med Imaging; 2024 Dec; 24(1):329. PubMed ID: 39627736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Definitive chemoradiotherapy with paclitaxel for locally advanced esophageal squamous cell carcinoma in older patients (PARADISE-1): a phase I trial.
    Hirata K; Yoshida K; Katada C; Watanabe A; Tsushima T; Yamaguchi T; Yamamoto S; Ishikawa H; Sato Y; Imamura CK; Tanigawara Y; Ito Y; Kato K; Kitagawa Y; Hamamoto Y
    BMC Cancer; 2024 Jul; 24(1):873. PubMed ID: 39030570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival comparison between open and thoracoscopic esophagectomy for node-negative esophageal squamous cell cancer: an ambispective cohort study.
    Jia X; Ren T; Chen P; Xin X; Zhang Y; Yang Y
    Surg Endosc; 2024 Dec; 38(12):7341-7351. PubMed ID: 39433581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of time to postoperative recurrence on the prognosis of patients with esophageal cancer post recurrence: exploratory analysis of OGSG 1003.
    Hori S; Yamasaki M; Yamamoto N; Harino T; Momose K; Yamashita K; Tanaka K; Sugimura K; Makino T; Takeno A; Shiraishi O; Motoori M; Miyata H; Kimura Y; Hirao M; Yasuda T; Yano M; Doki Y
    Esophagus; 2024 Oct; 21(4):472-483. PubMed ID: 39174706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy.
    Ji Z; Wang X; Xin J; Ma L; Zuo D; Li H; Su L; Lv X; Ge S; Zhang L; Liu Y; Zhang Y; Ding T; Deng T; Ba Y; Liu R
    J Immunother Cancer; 2024 Dec; 12(12):. PubMed ID: 39653554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Effect of the PNI and LSR in Patients with Esophageal Squamous Cell Carcinoma Patients Receiving Radiotherapy.
    Gao J; Li M; Wang Y; Wang Z; Chen X; Li H
    J Gastrointest Cancer; 2024 Nov; 56(1):26. PubMed ID: 39601941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Local excision for middle-low rectal cancer after neoadjuvant chemoradiation: A retrospective study from a single tertiary center.
    Chen N; Li CL; Wang L; Yao YF; Peng YF; Zhan TC; Zhao J; Wu AW
    World J Gastrointest Oncol; 2024 Dec; 16(12):4614-4624. PubMed ID: 39678786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial.
    Gao X; Ji K; Jia Y; Shan F; Chen Y; Xu N; Jia Z; Liu T; Yang N; Zhong H; Li C; Guo Z; Fan Q; Lin X; Zhang Y; Ren H; Yang H; Yao Z; Liu W; Wang ZM; Li B; Xia M; Shen L; Li Z; Ji J
    Nat Med; 2024 Jul; 30(7):1943-1951. PubMed ID: 38778212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.